Pharmaron Beijing Co., Ltd. Class H (DE:17Q1)
FRANKFURT:17Q1
17Q1 Stock Chart & Stats
€2.56
-€0.04(-2.45%)
At close: 4:00 PM EST
€2.56
-€0.04(-2.45%)
Day’s Range― - ―
52-Week Range€1.60 - €3.24
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.60B
Enterprise Value€41.80B
Total Cash (Recent Filing)€2.97B
Total Debt (Recent Filing)€7.08B
Price to Earnings (P/E)23.8
Beta0.68
Next Earnings
Aug 31, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.95
Shares Outstanding359,977,870
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-2.69
Price to Book (P/B)2.06
Price to Sales (P/S)2.20
P/FCF Ratio56.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.20Price Target Upside25.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.14
Revenue Forecast (FY)€2.04B
Bulls Say, Bears Say
Bulls Say
Integrated Discovery-to-manufacturing Service ModelPharmaron's end-to-end service offering — discovery, preclinical/clinical support, and CDMO manufacturing — creates durable client stickiness and cross-selling potential. Long client project cycles and bundled services raise lifetime value and help stabilize revenue across drug development stages.
Low Leverage And A Strengthened Balance SheetLow debt relative to equity gives the company financial flexibility to invest in capacity, weather biotech funding cycles, and pursue strategic projects. A stronger balance sheet reduces refinancing risk and supports long-term R&D and manufacturing commitments to clients.
Solid Operating Profitability And Reasonable MarginsSustained positive margins indicate structural pricing power and operational competence in specialized R&D and manufacturing services. Persistent profitability supports reinvestment and capacity expansion, enabling long-term scaling even as revenue growth moderates.
Bears Say
Weak And Volatile Free Cash Flow ConversionVolatile and modest free cash flow versus reported earnings limits internal funding for capex, dividends, or M&A. Recurring negative or thin FCF years raise reliance on external financing during investment cycles and reduce resilience to prolonged working-capital or billing timing issues.
Slowing Revenue Growth And Margin CompressionA decelerating top line combined with margin erosion suggests rising costs, pricing pressure, or mix shifts. Over the medium term this can constrain scalability and reinvestment capacity, forcing tougher commercial competition and potential margin normalization versus historical peaks.
Earnings Growth Negative And Middling Capital EfficiencyNegative recent EPS growth and only steady ROE indicate earnings momentum has stalled. Without accelerating returns or earnings, investor upside depends on operational improvements or higher growth, which may require sustained execution and additional investment with uncertain near-term cash payback.
Pharmaron Beijing Co., Ltd. Class H News
17Q1 FAQ
What was Pharmaron Beijing Co., Ltd. Class H’s price range in the past 12 months?
Pharmaron Beijing Co., Ltd. Class H lowest stock price was €1.60 and its highest was €3.24 in the past 12 months.
What is Pharmaron Beijing Co., Ltd. Class H’s market cap?
Pharmaron Beijing Co., Ltd. Class H’s market cap is €4.60B.
When is Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date?
Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date is Aug 31, 2026 which is in 78 days.
How were Pharmaron Beijing Co., Ltd. Class H’s earnings last quarter?
Pharmaron Beijing Co., Ltd. Class H released its earnings results on Apr 28, 2026. The company reported €0.023 earnings per share for the quarter, missing the consensus estimate of €0.026 by -€0.003.
Is Pharmaron Beijing Co., Ltd. Class H overvalued?
According to Wall Street analysts Pharmaron Beijing Co., Ltd. Class H’s price is currently Undervalued.
Does Pharmaron Beijing Co., Ltd. Class H pay dividends?
Pharmaron Beijing Co., Ltd. Class H does not currently pay dividends.
What is Pharmaron Beijing Co., Ltd. Class H’s EPS estimate?
Pharmaron Beijing Co., Ltd. Class H’s EPS estimate is 0.03.
How many shares outstanding does Pharmaron Beijing Co., Ltd. Class H have?
Pharmaron Beijing Co., Ltd. Class H has 359,977,870 shares outstanding.
What happened to Pharmaron Beijing Co., Ltd. Class H’s price movement after its last earnings report?
Pharmaron Beijing Co., Ltd. Class H reported an EPS of €0.023 in its last earnings report, missing expectations of €0.026. Following the earnings report the stock price went up 6.422%.
Which hedge fund is a major shareholder of Pharmaron Beijing Co., Ltd. Class H?
Currently, no hedge funds are holding shares in DE:17Q1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharmaron Beijing Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
11.22%
Trailing 12-Months
Asset Growth
15.52%
Trailing 12-Months
Company Description
Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a global contract research, development, and manufacturing organization (CRDMO) that supports the life sciences sector. Operating across North America, Europe, Mainland China, and other Asian regions, the company delivers comprehensive pharmaceutical research and development services worldwide. Its diverse operations are structured into five key divisions: Laboratory Services; Chemistry, Manufacturing and Controls (CMC) Solutions; Clinical Development Services; Biologics and Cell and Gene Therapy Services; and an "Others" category. Within its offerings, Pharmaron provides extensive laboratory support, including expertise in medicinal, synthetic, analytical, and purification chemistry, alongside computer-aided drug design. It also offers bioscience solutions such as in vitro and in vivo drug metabolism and pharmacokinetics (DMPK)/absorption, distribution, metabolism, and excretion (ADME) studies, as well as in vitro biology, in vivo pharmacology, and safety assessment, including specialized U.S. laboratory services. The company's CMC capabilities encompass process development, manufacturing, material science, pre-formulation, formulation development, manufacturing, and analytical development services. Additionally, it handles radiolabelled science and manages both early-stage clinical trials and broader clinical research with site management. Pharmaron also engages in business development and offers comprehensive contract research, development, and manufacturing for various pharmaceutical products. Established in 2004, Pharmaron Beijing Co., Ltd. is headquartered in Beijing, People's Republic of China.
17Q1 Stock 12 Month Forecast
Average Price Target
€3.20
▲(25.01% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Frontage Holdings Corp.
―
Viva Biotech Holdings
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---